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Is the Predominant
Mechanism of Sudden
Cardiac Death in Patients
With Chronic KidneyDiseasePatients with chronic kidney disease (CKD) undergo-
ing hemodialysis experience a high annual mortality
rate (7% per year) with 25% of all deaths due to
sudden cardiac death (SCD) (1). There has been
conjecture as to the mechanism of SCD.
This prospective study (Identiﬁcation and Char-
acterisation of Risk Factors for Atrial and Ven-
tricular Arrhythmias in Chronic Kidney Disease
Patients Using Implantable Cardiac Monitoring;
ACTRN12613001326785) aimed to document the ar-
rhythmic mechanism of SCD in a cohort of CKD
patients with preserved left ventricular (LV) function
on hemodialysis using an implantable cardiac monitor
(ICM). We recruited 50 clinically stable ambulatory
CKD patients receiving stable outpatient thrice-
weekly hemodialysis. Exclusion criteria included
severe LV dysfunction (LV ejection fraction <35%),
New York Heart Association class IV symptoms, pre-
existing pacemaker or implantable cardioverter-
deﬁbrillator in situ, and a previous history of clinical
ventricular tachyarrhythmias or syncope. Each patient
had an ICM (Conﬁrm, St. Jude Medical, St. Paul, Min-
nesota) implanted subcutaneously over the left upper
chest for continuous electrocardiographic monitoring.
Storage of the electrocardiogram was triggered
automatically when arrhythmic events fulﬁlled pre-
programmed cutoff criteria, including the following:
1) sinus bradycardia #40 beats/min for $4 beats;
2) sinus arrest with pauses/asystole $3 s; 3) high-
degree atrioventricular (AV) block (second- to third-
degree AV block) #40 beats/min lasting $3 s;
4) nonsustained ventricular tachycardia (VT) $125
beats/min, >16 beats lasting <30 s); 5) sustained VT
$125 beats/min, lasting $30 s; and 6) ventricular
ﬁbrillation.
Arrhythmias were characterized by their temporal
occurrence relative to hemodialysis sessions. Thelong interdialytic period (LIDP) was deﬁned as the
72-h break between hemodialysis sessions, whereas
the other two 48-h IDP were each deﬁned as the short
interdialytic period (SIDP). Conventional thrice-
weekly hemodialysis includes a single LIDP and 2
SIDPs. Patients underwent intensive follow-up every
2 weeks for device data download.
The arrhythmic event data were positively skewed,
so a logarithmic transformation of the data was per-
formed prior to analysis to ensure homogeneity of
variance. Analysis of variance with repeated mea-
sures was then performed comparing incidence rates
between each day.
The mean age of the study population was 66  11
years and 72% of the population was male. Partici-
pants had been receiving hemodialysis for a mean of
5  4 years. Comorbidities included diabetes mellitus
in 58%, hypertension in 86%, LV hypertrophy in 48%,
and ischemic heart disease in 48% of the population.
All study participants had a LV ejection fraction
>35%, and 58% had a LV ejection fraction >60%. Only
6% had QRS duration >120 ms. Of the total partici-
pants, 72% were taking a beta-blocker. Seven patients
had known atrial ﬁbrillation prior to ICM implanta-
tion (3 paroxysmal, 4 permanent).
After a mean follow-up of 12  4 months, there
were 6 deaths (12%); 5 deaths were unexpected and
classiﬁed as SCD. There was 1 non-SCD due to multi-
organ failure after elective orthopedic surgery. Of the
5 SCD patients, 2 underwent post-mortem examina-
tions that failed to identify an acute cause of death.
Another individual with witnessed out-of-hospital
SCD died within 24 h of hospital admission and
extensive investigation did not establish a cause of
death. All SCD events occurred during the LIDP with
severe bradycardia and ensuing asystole in 4 cases
recorded by the ICM as the terminal event (Figure 1).
ICM interrogation in the ﬁfth case was refused due to
cultural reasons. No ventricular arrhythmias were
recorded either preceding or following the bradycar-
dic event in any of the 4 cases. In the 5 patients, the
longest recorded pause prior to the SCD event was 2 s
with no reported episodes of high-grade AV block or
syncope. In addition, there was no evidence of QRS
widening accompanying bradycardia in the initial
phase of the event in any of the 4 patients with
recorded bradycardia at the time of death.
FIGURE 1 Electrocardiograms Demonstrating Severe Bradycardia With Ensuing Asystole at Time of Death
Electrocardiograms demonstrating severe bradycardia with ensuing asystole at time of death that were retrieved from the implantable cardiac
monitor of a sudden cardiac death patient.
Letters J A C C V O L . 6 5 , N O . 1 2 , 2 0 1 5
M A R C H 3 1 , 2 0 1 5 : 1 2 6 3 – 7 1
1264An additional patient was successfully resuscitated
after experiencing an in-hospital cardiac arrest with
sustained monomorphic VT after presenting with an
acute coronary syndrome. There were no cases of
polymorphic VT or ventricular ﬁbrillation recorded.
There were 1,488 signiﬁcant arrhythmia events
occurring in 22 patients (44%): bradycardia in 12
(24%); sinus arrest in 10 (20%); 2 AV block in 2
(4%); and nonsustained VT in 8 (16%). The ﬁnal day
of the LIDP had more events than all other days
(p < 0.001 by analysis of variance).
In CKD patients on hemodialysis who have pre-
served LV function, our study demonstrates forthe ﬁrst time that the vast majority of SCD are
due to bradycardia and asystole, rather than malig-
nant ventricular arrhythmias. These observations
raise the key question of whether bradycardia/asys-
tole as the terminal rhythm represents a primary
electrical event, or alternatively, a manifestation
of end-stage, irreversible myocardial failure in the
setting of profound biochemical, metabolic, and
structural disarray. These observations have poten-
tial implications for strategies to minimize SCD in
this population, the prescription of hemodialysis
to minimize the LIDP, and the role of beta-blockers
in CKD.
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Identiﬁes New Human
Collagen Genes Involved
in Cardiac RemodelingVentricular remodeling, a process involving mor-
phological changes in cardiomyocytes and the extra-
cellular matrix (ECM), has been linked to worsening
of clinical status and heart failure (HF) development.
In HF, remodeling initially occurs as a compensatory
response to preserve the structural integrity of the
myocardium, but progressive collagen deposition can
lead to cardiac ﬁbrosis and impairment of diastolic
and systolic function (1). Thus, we analyzed changesin the expression proﬁle of collagen-related genes in
patients with ischemic cardiomyopathy (ICM) and
examined the relationships with left ventricular (LV)
dysfunction.
We obtained 23 human LV tissue samples from
patients with ICM (13 men; mean age, 54  8 years)
with end-stage HF undergoing heart transplantation
and control donors (CNT) (8 men, 2 women; mean
age, 47  16 years). All control donors had normal LV
function (ejection fraction >50%) and no history of
cardiac disease. As an established condition for in-
clusion in the study, all selected samples displayed a
260/280 nm absorbance ratio >2.0 and RNA integrity
number $9. Transcriptome-level differences between
ICM and CNT samples were investigated by means
of large-scale screening of 23 heart samples with
the use of RNA-sequencing technology and fur-
ther validated by means of real-time (RT-PCR)
and Western blot analysis (Figure 1). These data
have been deposited in the NCBI Gene Expression
Omnibus (GEO) (retrieved by use of the GEO Series
accession No. GSE55296). We performed quantitative
RT-PCR assays in duplicate with the use of TaqMan
technology in the ViiA7 The Fast Real-Time RT-PCR
System (Applied Biosystems, Foster City, California);
collagen IV (COL4A5, Hs00166712_m1), collagen XIV
(COL14A1, Hs00964045_m1), and collagen XVI
(COL16A1, Hs00156876_m1) was obtained from Taq-
Man. Housekeeping genes GAPDH (Hs99999905_m1),
PGK1 (Hs99999906_m1), and TFRC (Hs00951083_m1)
were used as reference. Regarding the Western blot
analysis, tissue samples were transferred into Lysing
Matrix D tubes designed for use with the FastPrep-24
homogenizer (MP Biomedicals, Santa Ana, California).
Protein samples were separated by tris-acetate elec-
trophoresis on 3% to 8% polyacrylamide gels under
no-reducing conditions and transferred to a PVDF
membrane with the use of the iBlot Gel Transfer
Device (Life Technologies, Carlsbad, California) for
Western blot analyses. The primary detection an-
tibodies used were anti-COL4A5 rabbit polyclonal
(sc-11360) obtained from Santa Cruz Biotechnology,
anti-COL14A1 rabbit polyclonal (ab-101464) obtained
from Abcam, and anti-COL16A1 rabbit polyclonal
(A-96190) obtained from Sigma; monoclonal anti-
GAPDH antibody (ab-9484) from Abcam was used as
a loading control. We must note that patients with
end-stage HF are under heavy medical treatment,
and some therapies might inﬂuence mRNA levels.
We compared ICM and CNT samples, and we found
signiﬁcantly increased mRNA levels of 11 collagen
genes, such as COL9A1, COL11A2, COL14A1, and
COL16A1 (p < 0.05 for all), not previously described in
the cardiac remodeling process. A heat map and
